BELLUS Health Inc. (BLU) News
Filter BLU News Items
BLU News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest BLU News From Around the Web
Below are the latest news stories about BELLUS HEALTH INC that investors may wish to consider to help them evaluate BLU as an investment opportunity.
BELLUS Health Inc. Calls Special Shareholders’ Meeting in Connection with GSK AcquisitionMONTREAL, May 16, 2023--BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU.TO) ("BELLUS" or the "Company") today announced that the Superior Court of Québec has issued an interim order authorizing, among other things, the holding of a special meeting (the "Special Meeting") of shareholders of BELLUS ("Shareholders") on June 16, 2023. At the Special Meeting, Shareholders will be asked to consider and, if deemed advisable, to adopt a special resolution (the "Arrangement Resolution") approving the previousl |
BELLUS Health Reports First Quarter 2023 Financial Results and Business HighlightsLAVAL, Quebec, May 12, 2023--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company working to better the lives of patients suffering from persistent cough, starting with the development of camlipixant (BLU-5937) for the treatment of refractory chronic cough ("RCC"), today reported its financial and operating results for the quarter ended March 31, 2023. |
GSK Stock: A Value Trap or a Hidden Gem?GSK, formerly known as GlaxoSmithKline, is struggling after a complicated earnings season. |
BELLUS Health Announces Meeting UpdatesLAVAL, Quebec, April 26, 2023--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company working to better the lives of patients suffering from persistent cough, starting with the development of camlipixant (BLU-5937) for the treatment of refractory chronic cough ("RCC"), has announced the meeting and record dates for the special meeting of shareholders to be held in connection with the acquisition of the Company by GSK plc for US$2.0 |
Why Shares of Bellus Health Skyrocketed This WeekShares of Bellus Health (NASDAQ: BLU) jumped 105.1% this week as of Thursday afternoon, according to data provided by S&P Global Market Intelligence. The company, which received a $2 billion buyout offer from GSK (formerly known as GlaxoSmithKline) (NYSE: GSK), closed at $7.06 last week and reached a new 52-week high at $14.50 on Tuesday. The attraction for GSK is camlipixant, Bellus' late-stage pipeline candidate to treat adults with refractory chronic cough (RCC). |
Bellus Health (BLU) Stock Up 99% on $2B Buyout Offer From GSKBellus Health (BLU) gets an offer to be acquired by pharma bigwig, GSK for an approximate total equity value of $2 billion. The stock is up 99%, following the news. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayWe're starting off the day with a look at the biggest pre-market stock movers traders will want to keep an eye on Tuesday! |
Why Is Bellus Health (BLU) Stock Up 98% Today?Bellus Health (BLU) stock is taking off on Tuesday after the company announced a $2 billion acquisition deal with GSK (GSK). |
Why Is VirnetX (VHC) Stock Down 63% Today?VirnetX (VHC) stock is falling hard on Tuesday and it looks like this is connected to a special dividend offered by the company. |
Why Is ContraFect (CFRX) Stock Down 14% Today?ContraFect (CFRX) stock is dropping on Tuesday after the company revealed a notice from the Nasdaq and underwent a rally yesterday. |